MetaCap

Galectin Therapeutics (GALT) vs Greenwich LifeSciences (GLSI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences (GLSI) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 136.2% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -41.8% for GLSI. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $271.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GALT-49.72%GLSI+136.20%
+330%+125%-80%
Nov 21, 20251 yearNov 20, 2026
GALT0.00%GLSI-44.75%
+143%+27%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GALT versus GLSI key metrics
MetricGALTGLSI
Share price$2.69$19.25
Market cap$271.35M$282.56M
1-day change-4.27%-2.73%
YTD return-35.34%-8.38%
1-year return-49.72%+136.20%
5-year return+4.67%-41.84%
EPS (TTM)$-0.32$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-30.84M$-19.36M
52-week high$7.13$34.10
52-week low$2.03$7.78
Distance from 52-week high-62.27%-43.55%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+308.92%+198.70%
Average volume252.31K160.76K
Shares outstanding100.88M14.68M
Employees9—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GLSI has outperformed GALT by 185.9 percentage points over the past year.

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

GALT vs GLSI FAQ

Which is bigger, Galectin Therapeutics or Greenwich LifeSciences?

Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $271.35M for Galectin Therapeutics (GALT).

Which stock has performed better over the past year, GALT or GLSI?

GLSI returned +136.20% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.

Are Galectin Therapeutics and Greenwich LifeSciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons